IQVIA (IQV) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
12 May, 2026Executive summary
Q1 2026 revenue reached $4.151 billion, up 8.4% year-over-year, with strong organic growth in both Commercial and R&D Solutions segments.
Adjusted EBITDA was $932 million, up 5.5% year-over-year; adjusted diluted EPS rose 7.4% to $2.90, exceeding guidance.
Net income for Q1 2026 was $274 million, with GAAP diluted EPS at $1.61.
Free cash flow reached $491 million, a 15% increase year-over-year, representing 100% of adjusted net income.
$552 million of common stock was repurchased during the quarter; $1.2 billion remains authorized.
Financial highlights
Operating cash flow was $618 million, up 9% year-over-year.
Cash and cash equivalents at quarter-end were $1.947 billion; net debt was $13.886 billion.
Gross margin for Q1 2026 was approximately 32.6%.
Adjusted net income was $492 million for the quarter.
Net leverage ratio was 3.62x trailing twelve-month adjusted EBITDA.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at $17.15–$17.35 billion, with 150 bps from acquisitions and 100 bps FX tailwind.
Full-year adjusted EBITDA guidance maintained at $3.975–$4.025 billion.
Full-year adjusted diluted EPS guidance raised to $12.65–$12.95.
Q2 2026 revenue expected at $4.28–$4.34 billion; adjusted EBITDA $955–$975 million; adjusted diluted EPS $2.98–$3.08.
Guidance assumes stable FX rates as of May 4, 2026.
Latest events from IQVIA
- Strong Q1 growth, accelerating AI adoption, and robust capital deployment signal positive outlook.IQV
Bank of America Global Healthcare Conference 202613 May 2026 - AI-driven growth, robust data assets, and stable margins support a positive outlook.IQV
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day8 Apr 2026 - AI adoption, biotech growth, and new acquisitions drive optimism and margin expansion.IQV
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - AI-driven efficiencies and the Cedar Gate acquisition strengthen patient analytics and growth.IQV
Leerink Global Healthcare Conference 20269 Mar 2026 - 2025 results show robust growth, innovation, and governance, with all management proposals recommended.IQV
Proxy Filing27 Feb 2026 - Board recommends approval of all proposals except separating Chairman and CEO roles.IQV
Proxy Filing27 Feb 2026 - Strong 2025 results and 2026 outlook driven by AI, segment realignment, and robust demand.IQV
Q4 20255 Feb 2026 - Q2 revenue and profit margins rose, with record backlog and reaffirmed full-year guidance.IQV
Q2 20243 Feb 2026 - Strong R&DS and data-driven AI offset TAS volatility, supporting robust margins and growth outlook.IQV
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026